×
For best experience we recommend to activate Javascript in your browser.
Recombinant ICOSLG antibody (AA 250-300)
The Rabbit Monoclonal anti-ICOSLG antibody has been validated for WB. It is suitable to detect ICOSLG in samples from Human.
Quick Overview for Recombinant ICOSLG antibody (AA 250-300) (ABIN7449158)
Target
See all ICOSLG Antibodies
ICOSLG
(Inducible T-Cell Co-Stimulator Ligand (ICOSLG))
Antibody Type
Recombinant Antibody
Reactivity
All reactivities for ICOSLG antibodies
Human
Host
All hosts for ICOSLG antibodies
Rabbit
Clonality
All clonalities for ICOSLG antibodies
Monoclonal
Conjugate
All conjugates for ICOSLG antibodies
This ICOSLG antibody is un-conjugated
Application
All applications for ICOSLG antibodies
Western Blotting (WB)
Clone
BLR166J
Product Details anti-ICOSLG Antibody
(hide)
Binding Specificity
All epitopes for ICOSLG antibodies
AA 250-300
Purpose
Rabbit anti-ICOSL/B7-H2 Recombinant Monoclonal Antibody [BLR166J]
Immunogen
between AA 250 and 300
Isotype
IgG
Alternatives
(show)
Application Details
(hide)
Application Notes
01:01,00
Restrictions
For Research Use only
Handling
(hide)
Concentration
400 μg/mL
Buffer
Borate Buffered Saline (BBS) pH 8.2 with 0.1 % BSA and 0.09 % Sodium Azide
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C
Expiry Date
12 months
Target Details for ICOSLG
(hide)
Target
ICOSLG
(Inducible T-Cell Co-Stimulator Ligand (ICOSLG))
Alternative Name
ICOSL/B7-H2
Background
Background: ICOSL, also known as B7-H2, is a ligand for the T-cell-specific cell surface receptor ICOS. ICOSL acts as a costimulatory signal for T-cell proliferation and cytokine secretion, and also induces B-cell proliferation and differentiation into plasma cells. [taken from the Universal Protein Resource (UniProt) O75144].
Gene ID
23308
NCBI Accession
NP_056074
UniProt
O75144
Pathways
Production of Molecular Mediator of Immune Response , Activated T Cell Proliferation
Recently viewed
(hide)
Chat with us , powered by LiveChat